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Abstract
Background: Medical research must involve the participation of human subjects. Knowledge of patients'
perspectives and concerns with their involvement in research would enhance recruitment efforts, improve
the informed consent process, and enhance the overall trust between patients and investigators. Several
studies have examined the views of patients from Western countries. There is limited empirical research
involving the perspectives of individuals from developing countries. The purpose of this study is to examine
the attitudes of Egyptian individuals toward medical research. Such information would help clarify the type
and extent of concerns regarding research participation of individuals from cultural, economic, and political
backgrounds that differ from those in developed countries.
Methods: We conducted semi-structured interviews with 15 Egyptian individuals recruited from the
outpatient settings (public and private) at Ain Shams University in Cairo, Egypt. Interviews were taped,
transcribed, and translated. Thematic analysis followed.
Results: All individuals valued the importance of medical research; however most would not participate
in research that involved more than minimal risk. Individuals were comfortable with studies involving
surveys and blood sampling, but many viewed drug trials as being too risky. All participants valued the
concept of informed consent, as they thought that their permission to be in a research study was
paramount. Many participants had discomfort with or difficulty in the understanding several research
concepts: randomization, double-blind, and clinical equipoise. Trust in the physicians performing research
was important in deciding to participate in clinical research. The small sample size and the selection bias
associated with obtaining information from only those who agreed to participate in a research study
represent limitations in this study.
Conclusion: Overall, individuals in our sample recognize the value of medical research and have a great
deal of trust regarding medical research and their participation in research. There were, however,
concerns with the level of research risks associated with several types of medical research. Many also
demonstrated confusion with certain research methodologies. We recommend 1) enhanced educational
efforts regarding general research concepts to enhance the validity of informed consent and 2) further
survey studies in other areas of Egypt to determine the generalizability of our results.
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Background
Medical research involving human participants has
increased greatly in many developing countries during the
recent decade, motivated by the need to address the high
burden of diseases in these countries. The ethical conduct
of research specific to developing countries has been the
subject of recent discussions [1-3] and has been addressed
in several research ethics guidelines [4,5]. Issues raised by
these publications have included the relevance of the
research to the health needs of the community and the
country, avoidance of exploitation, and assurance that the
informed consent process is sensitive to the local context,
yet also representative of genuine, independent choice.
Since medical research requires the participation of
human subjects, high levels of patient recruitment are
required for a successful research agenda. Factors that
might affect willingness to participate in medical research
include patients' perceived benefits associated with their
participation in drug trials [6,7], confusion with research
methods such as blinding and randomization [7,8], the
level of patient understanding of information about the
research [9], and the level of trust patients place in inves-
tigators [9]. Knowledge regarding the understandings,
perspectives, and concerns of individuals with their
potential involvement in medical research would be
important with improving recruitment efforts, enriching
the informed consent process, and enhancing the overall
trust between investigators and the public. Such knowl-
edge would also help with devising strategies to improve
communications between patients and investigators.
Several qualitative studies have been performed eliciting
the views of patients regarding medical research from the
United States, Denmark, Australia, and Japan [10-13].
Such results, however, might not be generalizable to
developing countries that incorporate different ethnicity,
religions, cultures, economic, and political backgrounds.
Currently, there is limited empirical research involving
the perspectives of individuals from developing countries
[14,15] and from countries in the Middle East. Additional
studies would be helpful in further clarifying concerns,
misperceptions, and underlying themes regarding
research participation of individuals from these countries.
Accordingly, we conducted a pilot, qualitative study
involving individuals living in Egyptian society regarding
their perspectives on medical research. We expect that
information obtained from this study would be helpful to
individuals involved with research in developing coun-
tries, in general, as well as those involved with research in
Egypt and other Middle Eastern countries. A long-range
goal is that our results will be instrumental in designing
further comprehensive quantitative survey studies in the
international context.
Methods
Setting
We recruited a convenient sample of 15 individuals from
the outpatient clinic waiting areas from two of Ain Shams
University hospitals: Ain Shams University Specialty Hos-
pital, a semi-private university-based hospital, and Ain
Shams University Public Hospital, a public teaching hos-
pital. Both hospitals are situated in the metropolitan area
of Cairo and serve as referral hospitals for patients pre-
dominantly coming from northern (Lower) Egypt: Cairo
and areas of the Nile Delta, which fans out north of Cairo
to the Mediterranean coastline to include Alexandria and
Port Said. Urban life in Lower Egypt is marked by some
20–30 percent of the population living below the poverty
line and an illiteracy rate of approximately 55 percent.
Amidst the poverty, uneven development has led to
extremes in the distribution of wealth, as evidenced by the
emergence of an affluent class that stands in contrast to a
significant number of poor urban Egyptians who live in
overcrowded housing and inadequate access to clean
water, good quality health care, or education. Historically,
Lower Egypt has been more prosperous than the predom-
inantly rural Upper Egypt, which extends from 120 kilom-
eters south of Cairo to the border with Sudan. One third
of the population and half of Egypt's poor live in Upper
Egypt and it is also the area with the highest infant mor-
tality rates, 36 percent above the national average. Ethnic
minorities in Egypt include the Bedouin Arab tribes of the
Sinai Peninsula and the eastern desert, the Berber-speak-
ing community of the Siwa Oasis and the Nubian people
clustered along the Nile in the southernmost part of Egypt
[16].
Recruitment
Potential participants for our study were recruited from
the clinics' waiting rooms; they were either waiting for
their clinic appointments or were in the clinic area accom-
panying their family members who had clinic appoint-
ments. Two of the authors (SSK and MR) approached
individuals and briefly informed them of an interview
study involving determining individuals' attitudes
towards and experiences with medical research. If individ-
uals expressed interest, they were accompanied to a pri-
vate room near the clinic waiting areas where they
received further information about the study. If they
agreed to be interviewed, then verbal consent was
obtained and documented on the audiotape. The small
sample size and the selection bias associated with obtain-
ing information from only those who agreed to partici-
pate in a research study represent limitations in this study.
Interviews
Two of the authors (SSK and MR) received training in
interviewing techniques and used a semi-structured inter-
view guide that elicited open-ended responses from 15BMC Medical Ethics 2007, 8:9 http://www.biomedcentral.com/1472-6939/8/9
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research participants. All interviews were conducted in
colloquial Arabic. The interviewers were medical students
at Ain Shams University, who had no prior relationships
with the individuals recruited for the study. Interviews
lasted approximately 45 minutes and were audiotaped.
All of the interviews were conducted during a period of six
months. Audio recordings were transcribed in Arabic and
then translated into English. Interviewers helped partici-
pants complete a form that collected demographic infor-
mation.
Semi-structured interview tool
The survey tool consisted of open-ended questions that
assessed the attitudes of the individuals regarding the fol-
lowing broad categories:
• medical research and their willingness to participate in
different types of research
• studies with different types of risks
• research concepts (e.g., randomization, double-blinded,
equipoise)
• informed consent
• motivations of researchers
We were aware that the different words used to describe
research might convey very different meanings and hence,
might play a role in how individuals understand and per-
ceive the concept of research. Indeed, a previous study
showed that the term "medical study" was viewed as being
more positive and benign than the term "medical experi-
ment."[10] When interviewers asked participants how
they felt about research, interviewers initially used an Ara-
bic phrase (  abhas tibbiya) that denoted
medical study or research. However, it became apparent that
many participants equated this phrase with benign stud-
ies, such as survey research. Consequently, interviewers
used another Arabic phrase (  tagriba tibbiya)
that conveyed the meaning of medical experiment, which
helped ensure that participants understood that other
types of studies, such as drug trials, were the focus of the
interview. When appropriate, interviewers explicitly
explained the types of research studies that were the sub-
ject of the questioning.
Confidentiality
Participants were assigned a unique name different from
their actual name. These names were used during the
interview. This unique name was coded to the individual's
demographic form, which did not use the individual's real
name. After the tapes were transcribed they were
destroyed.
Analysis
An emergent coding approach was used, whereby two of
the authors (SSK and HJS) independently analyzed the
content of the transcribed texts to identify patterns and
themes that emerged from the data [17]. Themes and sub-
themes were segmented into categories according to a
consensus-driven coding scheme. In the final stage of
analysis, a matrix was developed to compare major
themes and patterns within and across interviews [18].
Research Ethics Committee approval
The research ethics committees at Ain Shams University
and the University of Maryland, School of Medicine gave
approval for the conduct of this study and approved the
mechanism of obtaining verbal consent.
Results
Demographic and background information
Of the 15 participants, 10 were female and 5 were male.
Nine were recruited from the private hospital and six were
recruited from the public hospital. Thirteen of the partici-
pants were from Lower Egypt, whereas the two resided in
Upper Egypt. The age range was from 19 to 69, with a
median age of 30 and an average age of 38 years. Three
participants had completed high school, eight had an
undergraduate college degree, and four participants had
attained a degree higher than undergraduate level. Of
these participants, eight were patients waiting for their
clinic appointments, while seven were accompanying
family members to the clinic. Eight participants were mar-
ried, all with children, while seven participants were sin-
gle. All but one participant was unemployed; nine were
considered to be in the lower income bracket (less than
1000 Egyptian pounds/month or less than $175/month
total household income). For each participant who agreed
to participate in the interview study, approximately four
were approached. Common reasons given for refusal to
participate in the study included time constraints or fear
of missing their appointments.
Description of findings
We identified several major themes from the analysis of
the data; these are listed in Table 1.
Perception of medical research
Good understanding of medical research
All participants had a good understanding of medical
research as a means of finding out more information
about a certain topic. For example, one male patient from
the private clinic said "In order for a theory to be proven there
must be evidence to substantiate it." A woman from the pub-BMC Medical Ethics 2007, 8:9 http://www.biomedcentral.com/1472-6939/8/9
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lic clinic said "In a research study we focus on a specific prob-
lem and begin to or try to research it from different angles until
we reach a certain result."
In response to being asked "Why is research important?"
several individuals mentioned that medical research is
important to "advance the field of medicine," it can "find
cures," "create medications to treat [diseases]"' and it
"generates new discoveries." One participant said "...this is
an age of emerging diseases and they have to find cures for
them," while another participant said "It's a means to study
the patient ...so that they can make the proper drug."
Positive attitude towards motivations of doctors performing research
When we asked participants what reasons motivated doc-
tors to do research, all said that they thought doctors
wanted to advance medicine, to find new treatments,
obtain new information, or to improve patient care.
When we asked if they thought that doctors do studies
only to promote their careers, nine of the participants
accepted the possibility that doctors do research to
advance their careers, but eight of these nine participants
did not believe career advancement was the sole reason
for doing research and that doctors are also doing research
to advance medicine and to help other patients.
Positive attitude towards research participation
Most participants (13 of 15) reported they would agree to
participate in a study even if there weren't direct benefits
to them. Eight of the respondents stated that their reasons
for participation would be the chance to help other
patients. One participant stated: "Yes it [medical research]
is important, because it's beneficial. If it won't benefit me, it
can be of benefit to others." Another one stated: "It doesn't
have to necessarily benefit me, but if it may help someone else
I would agree to participate." Another respondent stated:
"Yes, of course [I would agree to participate even if there
weren't any direct benefit] because the individual does not live
alone, but is rather a link in a large chain."
Importance of risk in the decision to participate in 
research
Importance of the degree of risk in determining willingness to 
participate in research
While the participants were willing to participate in
research even if there were no direct benefits, five of these
participants qualified such willingness based on the exist-
ence of side effects, specifically mentioning their reluc-
tance to participate in drug studies. For example, a
middle-aged woman attending the public clinic said; "But
a clinical trial would be something that's a little too difficult."
Table 1: Themes and sub-themes identified by analysis of interviews
Perception of medical research
Good understanding of clinical research
Positive attitude towards motivations of doctors performing research
Positive attitude towards research participation
Importance of risk in the decision to participate in research
Important of the degree of risk in determining willingness to participate in research
Willingness to participate in research decreases as the risk level of the study increases
Beliefs regarding benefits derived from research participation
Understanding of research concepts in a clinical trial
Discomfort with randomization
Variable understanding of concept of equipoise
Discomfort with doctor not knowing which drug is better
Discomfort with doctor being blind to treatment assignment
Issues with informed consent
Informed consent is an important value
Little discomfort with written informed consent
Mixed acceptance of proxy consent
Mixed reactions toward giving permission for children participation in research
Trust is an important value for patients
Concern with the prospect that research involves experimentationBMC Medical Ethics 2007, 8:9 http://www.biomedcentral.com/1472-6939/8/9
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Indeed, when we asked the participants
"How important are the risks to the study in deciding
whether or not to participate in a study?" all except one
respondent reported that the risks of a medical study
would influence their decision to participate. While three
of the respondents would not participate if there were any
risks involved, eleven qualified their answers. For exam-
ple, five respondents mentioned their fear of being in drug
studies or studies that will affect their health or lead to
physical harms. Two respondents distinguished between
the types of risks involved. For example, one respondent
said "It's not such a problem if it's an economic risk or an emo-
tional risk, but a health risk, that's difficult." Another
respondent told the interviewer "I'll take the questionnaire,
but I don't want to be ...experimented on....it's guinea pigs that
you experiment on." One participant mentioned the impor-
tance of weighing the risks and benefits and making sure
that the benefits are greater than the risks, another stated
that "there are limits to any risks" and another respondent
stated "It must have some guidelines that guarantee that it will
protect me."
Willingness to participate in research decreases as the risk level of 
the study increases
To obtain a better understanding of the role of risk in will-
ingness to participate in medical research, we gave the par-
ticipants examples of medical studies that involved
procedures with varying degrees of risk. We used studies
that ranged from a minimal risk level to higher risks.
These included a blood sampling study, a survey study
that inquired about sensitive information (such as medi-
cal condition, income level, etc), a study requiring a
biopsy of the skin, a study requiring endoscopy, and a
study involving the administration of an experimental
drug. The aggregate results are shown in Table 2.
a. Blood sample study
Most participants (13/15) agreed they would give a blood
sample in a study that would not directly benefit them.
Two respondents emphasized that giving blood is a nor-
mal activity in the clinic. Of the two participants that
objected to a blood sampling study; one stated "I'm afraid
of diseases" and the other said "I'm worried if a study requires
experimenting on me in particular...It's like I said, you usually
won't resort to entering a study or a clinical trial unless you feel
like there's something that you may gain from being in it...I
can't see it helping me."
b. Survey study requiring sensitive information
Almost all participants (12/15) reported they would agree
to participate in a survey study that asked for sensitive
information, even if there weren't any direct benefits
involved. One respondent stated: "If there are personal
experiences, I won't be shy to share this. I mean even if it is per-
sonal, but it may be of benefit to the study–or they'll find some
treatment for this or if they need to know it to find its underly-
ing reasons or something...then I'll say it. Another told the
interviewer: "Because if everyone of us just hides what they
find to be private, there won't be any studies. There won't be
anything new, we won't be able to find out what's wrong with
us and remedy [fix] it. So I would share." One respondent
from the private clinic qualified her answer by saying
"Most studies don't tie the information collected to any identi-
fying information. So I don't think I would mind this." Three
reported that they would not agree. One participant
explained: "Sometimes there are things that are too personal
that are hard to share." Another stated:"No, I wouldn't. Since
it won't be of any benefit to me. And I don't know, I wouldn't
feel comfortable answering their questions."
c. A study requiring a biopsy of the skin
Participants' reactions were mixed regarding their partici-
pation in a study involving a skin biopsy. Eight reported
that they would agree to such a study, although five of
these participants qualified their willingness to participate
by stating if the study did not involve too much risk. For
example, one stated: "I don't see any major risks in something
like that...I wouldn't participate if there were risks," while
another said "It depends on where it's from. If it doesn't
involve any risks then I'll agree." Six participants reported
that they would not agree to a biopsy for fear of the risks
involved. Responses included: "That sounds more dangerous
of course" and "No, that's a little too difficult to endure, it wor-
ries me. Anything that involves some kind of surgical procedure
worries me, even if it's a good physician." One participant did
not give an answer to this question.
d. A study requiring an endoscopy
The majority of the participants reported that they would
not agree to a study requiring an endoscopy. The main
reason given for refusal was due to the risks involved. One
individual stated: "No, that sounds like too much to endure.
God forbid, that's a procedure that's very invasive." Another
explained: "No." "Because I hear that endoscopy has many
risks involved." Finally, one individual stated: "No [I
wouldn't agree to participate in such a study]...I hear that
sometimes the instrument isn't good, and it may be contami-
Table 2: Relationship between the type of study and willingness 
to participate in the study. Studies are listed in order of 
increasing risk levels
Type of study Willingness to 
participate
Blood sampling study 13/15
Survey study involving sensitive information 12/15
Skin biopsy study 3/14
Endoscopy study 1/14
Drug trial 5/15BMC Medical Ethics 2007, 8:9 http://www.biomedcentral.com/1472-6939/8/9
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nated so it may cause some problems." The two respondents
who would agree to participate in such a study qualified
their willingness by saying "only if it doesn't have any risks"
or "if the doctor is someone that I've known for a long
time....then it would be okay."
e. Clinical trial involving an experimental drug
We asked participants their willingness to participate in a
drug trial that compared an experimental agent with an
approved drug on the market. We also said that that the
balance of risks and benefits of the experimental agent is
believed to be similar to that of the approved drug – con-
cept of clinical equipoise. While we were able to distin-
guish between respondents willing or not willing to
participate in such a study, many of the responses we
received indicated confusion with the basic underlying
concept of a drug trial. For example, while six of the 15
participants expressed their willingness to participate in
such a study, two of these participants said they would
participate only if experimental agent is thought to be bet-
ter than the approved drug. One said "if my doctor says it's
better, then I'll try it." While the other respondent said "but
the new drug must have a better impact than the old drug."
Two participants agreed to participate in the trial antici-
pating better results from the newer drug, although they
did not need a guarantee of better results, as the other two
participants. Of the eight who would refuse participation,
three could not understand why anyone would enroll in
such a trial if there was already an approved alternative on
the market. Two respondents expressed being scared of
drug studies, one did not want to be "experimented on,"
one stated he had allergies, and another respondent
doubted the concept of equipoise: "How do you know that
it has the same risks, when you still haven't tried it on people
yet? I can't go on someone's assumptions and expose myself to
such risks." One last respondent's answer indicated he did
not understand the concept of a drug trial.
Beliefs regarding benefits derived from research 
participation
We did not ask the participants specifically what they
thought about the prospects of obtaining benefits in med-
ical research. However, in response to several of the ques-
tions (e.g., regarding being in a drug clinical trial, proxy
consent when critically ill, and enrollment of children),
several individuals voiced a belief that medical research
could lead to benefits. For example, in response to being
asked to participate in a drug clinical trial, one respondent
said: "I definitely would agree to participate, but the new
drug must have a better impact than the old drug." In
response to allowing proxy consent when critically ill, an
individual said "I'm sure that they'll do what's in my best
interest, so yes." Finally, in response to being asked
regarding enrollment of children, one person said: "There
has to be mutual benefit," while another respondent said
"If I feel that the study will be of benefit."
Understanding of research concepts in a drug trial
Discomfort with randomization
We inquired as to how participants felt towards the proc-
ess of randomization. We asked them how they would feel
if treatment assignment in a drug trial would be deter-
mined by a coin toss, hence giving them a 50/50 chance
of receiving either the experimental agent or the approved
drug. Twelve participants felt uncomfortable with accept-
ing such a process and many of these did not seem to
understand the concept. Several participants reported feel-
ing worried and that this process might involve more risk.
One respondent said "No, I'm not comfortable with it. He
[the physician] should tell me what the risks and benefits of
each drug are and I should have the freedom to decide which of
the drugs I want [I'll take]." Another stated "I don't like the
idea of it being random. I know that one that's on the market
is available in the pharmacy, and there's the newer one. I'll just
take the older one." Another one said: "This random selection
method is not guaranteed [safe] at all...It's like I said, it's just
not safe. I just can't see how it can be safe to randomly assign
something in medicine [medical care]." Three participants
did not have difficulty with such a selection process. These
participants had varied backgrounds in terms of age, edu-
cations, and type of clinic they were attending (public vs.
private).
Variable understanding of concept of equipoise
After telling the participants again that there is uncertainty
of the relative risks and benefits between the experimental
agent and the approved drug and that the aim of the clin-
ical trial was to determine which drug is better, we asked
them if it mattered which intervention they received. Eight
participants had no preference, three preferred the new
drug, two preferred the existing drug, and one participant
stated a preference for the drug that had the least side
effects.
Discomfort with doctor not knowing which drug is better
We asked participants their thoughts regarding that physi-
cian-investigators are uncertain of which drug would be
best for them. Most participants (12/15) reported discom-
fort with such uncertainty. Many expressed disbelief that
the physician-investigator would not know which drug is
better for them. For example, one respondent said: "I don't
know, I'd be very surprised how my doctor doesn't know, I
might be worried how he's a doctor and doesn't know. He's spe-
cialized in this and doesn't know, so how should I feel but wor-
ried." Another one said: "Uncomfortable is not a term that's
enough to describe how I feel...I go to the doctor with my health
in their hands, which is the most precious thing to me. The fact
that there's some knowledge that they lack, which will affect my
health, I see that as a big problem." Another one said: "I'll beBMC Medical Ethics 2007, 8:9 http://www.biomedcentral.com/1472-6939/8/9
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very irritated because the doctor must be aware of everything,"
and another said "If the doctor doesn't know, of course I'm
going to be worried."
Discomfort with doctor being blind to treatment assignment
We asked the participants how they would feel about the
physician-investigator not knowing to which drug that
they would be assigned. Five respondents would not
accept to be in such a study: three said they needed to
know which drug they were receiving, while the other two
stated that their doctor had to know which drug they were
receiving. Responses from five respondents indicated they
lacked an understanding of the physician-investigator
being blinded to the treatment option. Three participants
said they would participate in such a study, but would be
either "worried" or uncomfortable with such a situation.
Two respondents would agree to participate in such a
study, concluding that this study made them feel more
comfortable about the results that would be generated,
since the results wouldn't be biased. For example, one
stated "I'm more comfortable in a situation where the conclu-
sion was reached in a logical way. Where there isn't external
influence, not from the physician, not from the company, but
from my personal experience [with the drug]" while the other
respondent said: "I think I might have more trust in his opin-
ion as a result, since he won't be influence"
Issues with informed consent
Informed consent is an important value
We asked participants if it were important for them to give
their permission to be in a research study. All participants
valued the importance of informed consent and some
framed their answer in the language of rights. For exam-
ple, one respondent said: "Definitely, it's important to
respect the rights of a patient." Another individual said: "Yes,
definitely, since you have to ask the patient first and everyone
has this right." One individual told the interview: "Yes, of
course...Aren't I the one that's going to join with my body and
my health? I mean, who else would they ask."
We also presented to the participants a scenario of an
investigator wanting to do a research study with the use of
the left-over blood from their blood samples that had
been obtained for clinical purposes. We asked if it would
be appropriate for the investigator to use the blood with-
out their permission. Of the15 participants, 13 said it
would be okay mainly because the blood had already
been taken.
Little discomfort with written informed consent
We told the participants that for the current interview
study, they only had to give verbal consent, but for many
other types of studies, an investigator would probably ask
them to sign documents stating they had given informed
consent. We asked them how they would feel with signing
such documents. Of the 15 participants, 13 felt comforta-
ble with giving written informed consent. However, two
respondents had hesitation with signing their names,
both were women in their thirties and both were at the
public clinics. One of these participants, who had a bach-
elor's degree, was afraid that their signature would mean
that he or she would feel obligated to continue in the
study despite a desire to withdraw. The other individual,
whose highest level of education was high school, was
afraid that the document would "fall in the wrong hands."
Mixed acceptance of proxy consent
We asked participants if they would agree to have a family
member give proxy consent for their participation in a
study if they were critically ill and could not make deci-
sions for themselves. Ten participants reported they
would not agree to proxy consent. Six were women of
whom five were from the private clinics and four were
married. Of the four men who were refusing proxy con-
sent, one was from the private clinic and three were from
the public clinic. A variety of reasons were given for such
refusal. For example, one participant expressed concern
about being enrolled in a study when critically ill:"No, it
has to be me [who gives consent]; not even my husband."
Another participant said: "I'd like it to be my decision, so that
I take full responsibility for whatever the outcome is." Finally,
another person said "Too ill to speak? I'm in a coma? No, I
won't agree."
In contrast, five participants would agree with proxy con-
sent; four were women and one was a man. One partici-
pant said "I'm sure that they'll do what's in my best interest,
so yes," while another said "Yes, it's okay for them to ask my
husband or my children."
Mixed reactions toward giving permission for children participation in 
research
We asked the participants if they would allow their chil-
dren to participate in research. Six of the 15 respondents
were not agreeable to such a concept. Four of these
respondents were women (three single, one married),
while two were men. Of the nine participants who said
they would agreed to enroll their children in research, five
(all women), specifically mentioned that their permission
would be conditional. For example, three stated the study
would need to be associated with benefits for their chil-
dren. Another said that she would "be hesitant if it has
risks" and another respondent mentioned that there
needs to be assurances that the study would not involve
experimenting on her child. Hence, of the 11 respondents
who either would refuse enrolling children research or
would conditionally enroll, nine were women.BMC Medical Ethics 2007, 8:9 http://www.biomedcentral.com/1472-6939/8/9
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Trust as an important value
Throughout the interviews, the theme of trust emerged as
an important value for individuals when considering par-
ticipation in research. For example, several respondents
mentioned that for them to participate in research, they
would need to trust the physician asking them to enroll in
the research. One respondent stated: "I have to be able to
feel like I can trust them. As soon as I'm certain that I can trust
them, then I'd be able to agree to participate." Another
respondent said: "I think I'd be more likely to agree if my phy-
sician asked me...If I can't trust my physician then who can I
trust?"  Another participant, a nineteen-year old female
college student, reported the importance of physicians'
involvement in the research, since she would trust them
more than other health care professionals.
In response to a study involving endoscopy, one partici-
pant stated: "No, I'd be afraid...If it's a doctor that I've known
for a long time... then I might agree to the endoscopy... [If it
was a doctor that I did not know well] It would depend on how
much I trust them"
When asked about participating in a study in which the
risks and benefits of the experimental drug was similar to
that of the approved drug, one respondent said "I'll partic-
ipate if my doctor says it's okay for me to participate.... I trust
my doctor one-hundred percent."
When asked about participating in a study in which phy-
sicians would be blinded to the treatment assignment, a
respondent mentioned that whether or not he would be
willing to enroll in the study would "depend on how much
I trust them." Another respondent stated: "I'll trust the phy-
sician if he explains this to me first, it will make me feel more
comfortable."
Concern with the prospect that research involves 
experimentation
Throughout the interview, participants mentioned many
times their thoughts that research is an enterprise that can
be associated with experimentation, a concept that
instilled fear into them. The mention of such statements
transcended age, gender, and clinic type. For example, sev-
eral respondents viewed drug trials as akin to experimen-
tation. A 26 year-old male from the public clinic
mentioned "I'll take the questionnaire study, but I don't want
to be in a situation where I'll be experimented on. First of all,
it's guinea pigs that you experiment on." A 69 year-old male
from the private clinic mentioned that "I may participate in
[a study] with an exception of those that involved experiment-
ing with drugs on me." A 29 year-old woman from the pri-
vate clinic expressed that "I wouldn't do that. I won't let them
experiment with a drug on me." A 63 year-old female from
the private clinic mentioned "No, I won't agree. I don't want
anyone to experiment on me." When told that doctors are
blinded to study treatment, a 26 year-old male from the
public clinic said: "No, I'm not comfortable with it. Because
we're humans and not lab animals. Because there's a degree of
degradation to a human being by experimenting on them."
When asked about enrolling children in a drug clinical
trial, a 40 year-old woman from the private clinic men-
tioned: "No of course not. If they just want to monitor him
that's okay, but they can't experiment on him."
Discussion
This study reveals several important initial insights regard-
ing the perspectives of Egyptians toward medical research
that might be applicable to individuals in other develop-
ing countries. First, the individuals in our sample had a
good general understanding of the concept of research.
They also understood that the goal of medical research is
to advance medical progress that will help future patients.
Also, most of the respondents would participate in medi-
cal research, even if there were no prospect of direct bene-
fits for their participation.
This interest in participating in medical research, however,
was conditional on their perceived risks associated with
the research. As the interviews progressed and when
respondents were asked to comment on different types of
medical studies, it became apparent that many were hesi-
tant with participating in studies that presented greater
than minimal risks. For example, most participants found
studies involving surveys and the giving of blood samples
to be acceptable. However, the willingness to participate
decreased with greater degrees of perceived risks associ-
ated with the research (e.g., endoscopy and drug trials).
In addition to concerns with risks, discomfort with drug
trials might also be related to a general unfamiliarity with
randomized drug trials. Furthermore, throughout the
interview, when the subject of drug trials came up, many
respondents would associate such studies with experi-
mentation, to which they found to be unacceptable and
degrading to humans. Finally, another factor contributing
to hesitation to participate in clinical trials might be due
to the realization that such trials are funded by foreign
pharmaceutical companies, which might engender the
notion that wealthy foreign establishments want to use
Egyptians as 'guinea pigs' to test drugs that they could not
otherwise test on their own citizens. Distrust of the
motives of scientists from developed countries was
observed in an informed consent study involving a West
African country [19]. Future studies involving individuals
from the Middle East should be performed to determine
the presence, if any, of distrust towards foreign investiga-
tors.
We also found that several research methods caused anxi-
ety, discomfort, and confusion among the participants.BMC Medical Ethics 2007, 8:9 http://www.biomedcentral.com/1472-6939/8/9
Page 9 of 12
(page number not for citation purposes)
For example, many did not feel comfortable with nor
understood the need for randomization. Investigators in
other countries have also uncovered discomfort and mis-
understanding with the concept of randomization. A
study involving Danish patients with cancer and inflam-
matory bowel disease also found that many had a nega-
tive or a hesitate view of randomization and that several
would have wanted to choose the treatment option them-
selves [11]. A focus-interview study of Japanese individu-
als also discovered that many had a feeling of repulsion
towards randomization [13]. An Australian study found
that many patients disliked being part of an experiment
and patients' willingness to join a clinical trial was nega-
tively associated with uncertainty of treatment allocation
[20]. A study involving oncology patients found that only
one-third of the respondents would consider taking part
in a trial comparing different treatments where treatment
was selected at random by a computer [12]. A recent qual-
itative interview study involving participants involved in
six different randomized controlled trials involving inter-
ventions to prevent or ameliorate an infectious disease in
Africa and the Caribbean found that there it was typical
for participants not to know how they would be assigned
to the intervention groups [14].
Many participants in our study sample were also confused
and concerned with the concept of doctors being blinded
to their study drug assignment. Only two participants real-
ized the scientific value of blinding in a research study.
The most difficult concept for the participants to under-
stand was that of clinical equipoise. Several participants
expressed their preferences for either taking the experi-
mental or the approved drug. More importantly, most
participants expressed disbelief that their doctors would
not know which study drug would be better. In a previous
study involving oncology patients, investigators found
that approximately one in four patients thought that the
doctor would really know which study drug was better in
a clinical trial and nearly three quarters thought that the
doctor would ensure that they would get the study drug
that was more efficacious [12]. Cassileth and colleagues
also found that a high proportion of patients believed that
doctors really know which of the study drugs was best
[21]. Other studies have also observed that patients think
that the experimental drug might be better and hence,
unwilling to be randomized to a placebo arm of a clinical
trial [13,22]. Such confusion regarding equipoise might
also explain why there was difficulty understanding the
requirement for randomization and the need for research
to be designed to determine the relative efficacy of drugs.
Several participants in our study associated scientific
design methods (i.e., randomization and blinding) with
"experimentation," a word that imparted a negative view
of research. The use of such research methods was seen as
being a barrier to their participation in research. It is
important that investigators are aware of these attitudes
and try to enhance patient understanding of the purposes
of research methods. Fallowfield and colleagues found
that further information can increase willingness to partic-
ipate in clinical trials [23]. However, other studies have
documented that research subjects do not understand
research concepts even when research staff specifically
explain these concepts and practices to them [9,19,24].
The failure to understand these important research design
methods has strong implications on obtaining a valid
informed consent.
Difficulty understanding and accepting the concept of
blinding and equipoise might be due to the phenomenon
of the therapeutic misconception [25,26], whereby partic-
ipants in a research study believe that they are receiving
best medical care. Such beliefs would make it difficult to
believe that there are no differences between the study
interventions and that their doctor would not know
which study drug would be best for them. Indeed, we
uncovered subtle indicators of the therapeutic misconcep-
tion throughout the interviews. For example, participants
thought that medical research represents treatment or has
the same goal as medical care. Specifically, several partici-
pants expressed a greater willingness to volunteer for
research if there were benefits to themselves or their chil-
dren. Other studies have also found that patients enrolled
in drug trials expect to receive personal benefits, despite
receiving contrary information [14,27]. Studies involving
patients from Western countries also reveal their discom-
fort with randomization, blinding, and equipoise, which
has been attributed to the therapeutic misconception and
with patients believing that physicians would know "what
is best" for their patients [8,11,12].
Our results regarding the informed consent process also
question the existence of any sharp division between
developed and developing countries. A principle of West-
ern ethics is that the individual acts as an autonomous
agent, whereas in many cultures in developing countries,
the individual is viewed in the context of the social group
[28-30]. Accordingly, it has been questioned whether it is
possible to have one internationally agreed standard of
informed consent in medical research, because the con-
cept of individuals making personal decisions independ-
ent of the family or the community is not common to all
cultures [28,30]. However, all of the participants in our
study valued the concept of informed consent, as they
thought their permission to be in a research study was par-
amount. Several participants expressed this concept in the
language of rights. Studies on informed consent from
other developing countries have also shown that individ-
uals participating in research desire to make their own
decisions regarding participation [19,31]. We also foundBMC Medical Ethics 2007, 8:9 http://www.biomedcentral.com/1472-6939/8/9
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little discomfort with the concept of providing a written
signature on informed consent forms, as only two partici-
pants found signing such documents threatening. This
observation is contrary to the general viewpoint that
insistence on having a signed consent form might not
always be appropriate for many individuals in developing
countries [2,27,32].
However, rather than being dependent on a concept of a
homogeneous culture existing in any one region or coun-
try, notions of autonomy or the acceptability of written
informed consent may very well depend on other factors
within a region, such as varying education levels and the
different degrees of modernity that might exist between
urban and rural communities, which might reflect the
uneven process of globalization of ideas and practices that
has otherwise facilitated convergence between different
cultures [33].
For example, until recently, Egyptians were only asked to
give their signatures for birth certificates, marriage certifi-
cates, identification documents, and during buying and
selling property. Accordingly, the requirement for a signa-
ture on other written documents had been viewed with
suspicion, particularly if the signatory is illiterate and can-
not validate the contents of the document. Now however,
particularly in urban areas and among those with a higher
level of education, more people are opening bank
accounts, getting loans and using credit cards, all of which
require the use of signatures (personal communication:
authors SE-K and SSK). Hence, our results might have
been due to the inclusion of participants with higher edu-
cational levels and who have been exposed to financial
practices that are more modern compared with those in
rural areas of Egypt.
Hence, instead of culture itself, which is increasingly
being viewed as internally heterogeneous and dynamic
[33], perspectives on medical research might be more
reflective of the specific local context within any one
country. This notion of the heterogeneity of cultures has
important implications for institutional review boards
that review the acceptability of the conduct of research in
heterogeneous communities.
Our results showed a mixed reaction regarding the accept-
ance of proxy consent for research participation when in a
critically ill state and one could not decide for themselves.
Egyptian society is a family-oriented society and hence,
one might expect that family decision making would be
acceptable, similar to what occurs in other developing
countries [31,34]. Our seemingly contrary results might
be explained by proxy consent being a novel concept in a
society in which individuals are not often asked to partic-
ipate in drug trials. The finding that many women would
refuse enrollment via a proxy consent mechanism might
be attributed to the high education level of our study sam-
ple, which might lead to a more equal power relationship
between health professionals and patients. Results might
differ in rural areas of Egypt where the influence of family
elders or male authority figures are more dominant in
health care decision making [31,35]. A majority of the
participants were not comfortable with enrolling children
in medical research. Many cited a concern with the risks or
stressed there needed to be some assurance of benefits
before having their child enrolled in research. This con-
cern with risks and benefits regarding children participa-
tion was shown in another study involving participants in
a developing country [27].
An important theme that emerged in many aspects of the
interviews was the importance of trust. Indeed, many par-
ticipants expressed that their participation in medical
research requires a trusting relationship between patients
and physicians and several expressed that such trust
already exists with their physicians. Such findings make
clear that a relationship built on trust with the medical
care provider is essential not only to medical care, but also
to future medical research endeavors in Egypt. The exist-
ing trust that Egyptians have with their physicians was val-
idated when most of the participants did not think that
physicians performed research only to advance their
careers. Many who thought that career advancement was
a motivating for the conduct of research also thought that
this was acceptable, because they believed that investiga-
tors are also motivated to advance medicine and help
future patients. Accordingly, clinical investigators in Egypt
should anticipate a large degree of trust and hence, will-
ingness to participate in medical research on the part of
most patients. One concern associated with a large degree
of trust is that patients might adopt a more passive role in
the informed consent process and seek less information
regarding the study.
There are several limitations to this study. First, our sam-
ple was limited to those who agreed to participate in a sur-
vey study and hence, it is possible that those who rejected
participation would add different insights regarding the
acceptability of research and the existence of trust occur-
ring in Egyptian society. Second, our sample size was
small and hence, our results might not be generalizable to
other parts of Egypt as well as to other Middle Eastern
countries. Indeed, our sample was more representative of
the culture and attitudes of the northern Nile Delta
region; varying attitudes might exist among the Sa'ayda
and Noubian Egyptians in southern (Upper) Egypt and
the Bedouins in Sinai. Third, the education level of our
participants was higher than the median level of Egyptians
from other parts of the country. As discussed above, differ-
ences in culture, education, and socioeconomic back-BMC Medical Ethics 2007, 8:9 http://www.biomedcentral.com/1472-6939/8/9
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ground among different areas in Egypt might have
influenced the results regarding written informed consent,
views about individualized decision making, and the
understanding of the general concept of research. Despite
the high education levels of our sample, many still had
difficulty understanding basic research design concepts.
Such difficulty would be even more extensive in rural
areas, where higher illiteracy rates exist. Also, despite the
small sample size, certain perspectives revealed regarding
medical research, e.g., the reluctance to assume greater
than minimal risk, the concerns with drug clinical trials,
and the importance of trust in decisions regarding partic-
ipation, might reflect the general attitudes of Egyptian
society and those in other developing countries
[13,14,27]. As qualitative research methodology is used
primarily to generate, rather than test hypotheses, our
results will serve as the basis for future studies incorporat-
ing highly structured surveys for broader distribution.
Conclusion
While our findings require validation in a larger sample
that includes other areas in Egypt and other developing
countries, we are able to make several recommendations.
First, there needs to be enhanced educational efforts
directed towards the lay public on fundamental issues
regarding research design concepts, as well as the distinc-
tion between research and medical care. Researchers
should also receive additional training on explaining
research concepts in understandable language. Further
empirical research is needed to measure the effect of crea-
tive interventions to improve participants understanding
of these concepts. These issues have strong implications
for achieving a valid informed consent.
Second, individuals are fearful of the risks inherent in
medical research and therefore, investigators and mem-
bers of research ethics committees need to give assurances
that procedures will be in place that minimize these risks
and enhance the protection of their rights and welfare.
Third, many patients and members of the lay public rec-
ognize the value of informed consent and the concept of
them providing their permission for their participation in
medical research. Accordingly, undergraduate and gradu-
ate curricula, and especially medical and paramedical
school training, should include familiarization with the
concepts of research ethics and the need for the valid,
informed consent of participants before their enrollment
into any research project.
Finally, investigators need to know that individuals are
willing to participate in medical research, because they
recognize the value of such research towards advancing
the field of medicine and they are trustful of the medical
profession. However, such trust might be fragile and
hence, a strong system of research ethics education and
ethics review would help ensure that such trust is main-
tained.
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